SCHEMBL2688265

SCHEMBL2688265

Cc1nc2cc(-c3nc4ccccc4o3)ccc2n1C1CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.47
▸ NPC1 O15118 7/20 0.47
▸ KDM4E B2RXH2 7/20 0.47
▸ HPGD P15428 6/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ RAB9A P51151 5/20 0.47
▸ HCRTR1 O43613 2/20 0.47
▸ NFKB1 P19838 2/20 0.47
▸ STAT1 P42224 2/20 0.47
▸ NFKB2 Q00653 2/20 0.47
▸ RELA Q04206 2/20 0.47
▸ HSD17B10 Q99714 4/20 0.46
▸ MAPT P10636 3/20 0.46
▸ USP2 O75604 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16015419 0.96 ALDH1A1 (0.44) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2687957 0.94 EP300 (0.48) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2687060 0.94 KDM4E (0.54) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2688684 0.93 MET (0.44) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2686300 0.92 ALDH1A1 (0.46) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2686439 0.91 SMN1; SMN2 (0.46) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
Dimethylamine SCHEMBL2687204 0.90 MET (0.42) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2688665 0.87 USP2 (0.42) ALDH1A1NPC1KDM4EHPGDSMN1; SMN2
SCHEMBL2687827 0.84 LMNA (0.46) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL10219571 0.83 CCR5 (0.46) ALDH1A1KDM4ESMN1; SMN2USP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 — — US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 — — EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 ALDH1A1 1772/4885NPC1 525/4885KDM4E 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback